Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the follow-on offering of 8,050,000 shares of common stock of…
Davis Polk advised the several underwriters in connection with the follow-on offering of 5,263,158 shares of common stock of Natera, Inc. for total gross proceeds of approximately $100…
Davis Polk advised the underwriters in connection with an initial public offering of 9,250,000 shares of common stock of Alector, Inc. at $19.00 per share, for total gross proceeds of $175…
Davis Polk advised the sole book-runner in connection with the SEC-registered secondary offering of 10,835,145 shares of common stock of NeoGenomics, Inc. by the selling stockholder, GE…
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 7,500,000 shares of common stock of…
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the approximately $125 million public offering of common stock of…
Davis Polk advised the representatives of the underwriters in connection with the follow-on offering of 5,175,000 shares of common stock for Natera, Inc. for total gross proceeds of …
Davis Polk advised the joint book-running managers for a $50 million public offering of common stock by Ardelyx, Inc. The common stock is listed on the NASDAQ Global Market under the…
Davis Polk advised the joint book-running managers in connection with the $86.25 million public offering of common stock of Coherus BioSciences, Inc.
Based in Redwood City, California,…
Davis Polk is advising Shire plc on the $2.4 billion sale of its Oncology business to Servier S.A.S. The transaction has been approved by the board of directors and is expected to close in…